According to the EORTC 1999 criteria, <sup>18</sup>F-FDG PET/CT-based treatment response revealed CR in 14 patients (<sup>18</sup>F-FDG PET/CT CR), PR in 11 patients (<sup>18</sup>F-FDG PET/CT PR) and progressive disease in four patients (<sup>18</sup>F-FDG PET/CT PD).
All PD and PR patients were found to be metabolic responders on 18F-FDG-PET/CT; however, among the 62mRECIST SD patients, 18 (29%) were classified as metabolic non-responders.